Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
59M
-
Number of holders
-
145
-
Total 13F shares, excl. options
-
64.7M
-
Shares change
-
-894K
-
Total reported value, excl. options
-
$490M
-
Value change
-
-$25.8M
-
Put/Call ratio
-
1.15
-
Number of buys
-
66
-
Number of sells
-
-71
-
Price
-
$7.57
Significant Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) as of Q1 2025
171 filings reported holding CGEM - Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) has 145 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.7M shares
.
Largest 10 shareholders include MPM BIOIMPACT LLC (7.65M shares), BVF INC/IL (5.75M shares), BlackRock, Inc. (4.22M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (3.86M shares), Lynx1 Capital Management LP (3.22M shares), VANGUARD GROUP INC (3.04M shares), CITADEL ADVISORS LLC (2.75M shares), Blue Owl Capital Holdings LP (2.44M shares), Kynam Capital Management, LP (2.34M shares), and FRANKLIN RESOURCES INC (2.22M shares).
This table shows the top 145 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.